Among the patients who received irinotecan with or without another anticancer agent, grade 4 neutropenia was noted in 40–57% of the patients with UDP-glucuronosyltransferase (UGT) 1A1*28 (a polymorphism in the promoter region of the UGT1A1 gene) homozygosity, whereas neutropenia was only observed in 15% or less of the patients with wild-type alleles. Here, B3GAT2 is linked to Decreased total neutrophil count.